Original Articles: PDF OnlyPHASE II TRIAL OF PACLITAXEL IN PATIENTS WITH ADVANCED COLON CANCER PREVIOUSLY UNTREATED WITH CYTOTOXIC CHEMOTHERAPY AN EASTERN COOPERATIVE ONCOLOGY GROUP TRIAL (PA286)Einzig, Avi I.1,*; Neuberg, Donna2; Wiernik, Peter H.3; Grochow, Louise B.4; Ramirez, Guillermo5; O'Dwyer, Peter J.6; Petrelli, Nicholas J.7Author Information 1 Albert Einstein College of Medicine, Department of Medicine, Bronx, NY. 2 Dana Farber Cancer Institute, Division of Biostatics, Boston, MA. 3 Montefiore Medical Center, Department of Oncology, Bronx, NY. 4 John Hopkins University, Baltimore, MD. 5 University of Wisconsin Hospital, Madison, WI. 6 Fox Chase Cancer Center, Philadelphia, PA. 7 Roswell Park Cancer Center, Buffalo, NY. * Address for correspondence: Department of Medicine, Albert Einstein College of Medicine, 1825 Eastchester Road, Bronx, NY 10461, USA. American Journal of Therapeutics: November 1996 - Volume 3 - Issue 11 - p 750-754 Buy Abstract Paclitaxel was administered as a 24-h continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinoma of the colon or rectum. Nineteen patients were evaluated for toxicity and 15 were assessable for response. There were no complete or partial responses, and toxicity present was primarily neutropenia. This study found that paclitaxel as a single agent does not have activity in adenocarcinoma of the colon or rectum. © Williams & Wilkins 1996. All Rights Reserved.